Checkpoint inhibitor-induced uveitis: a case series

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 256, Issue 1, 2018, Pages 187-191

  Conrady, Christopher D ^a   Larochelle, Marissa ^a   Pecen, Paula ^b   Palestine, Alan ^b   Shakoor, Akbar ^a   Singh, Ajay ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune uveitis; Checkpoint inhibitors; Metastatic cancer

Indexed keywords

ATEZOLIZUMAB; CHECKPOINT KINASE INHIBITOR; FLUOCINOLONE ACETONIDE; IPILIMUMAB; METHYLPREDNISOLONE; NIVOLUMAB; PEMBROLIZUMAB; PREDNISONE; STEROID; TRIAMCINOLONE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLURRED VISION; BREAST CANCER; CASE REPORT; CENTRAL RETINA ARTERY OCCLUSION; CHILL; CHOROID DISEASE; CHOROIDAL THICKNESS; CHOROIDITIS; CILIARY BODY; CLINICAL ARTICLE; CLINICAL FEATURE; COLON ADENOCARCINOMA; DECREASED APPETITE; DRUG WITHDRAWAL; EYE FUNDUS; FEMALE; FEVER; HEADACHE; HEARING IMPAIRMENT; HUMAN; HYPEREMIA; IMMUNOTHERAPY; INSOMNIA; MACULOPAPULAR RASH; MALE; MENTAL DISEASE; METASTATIC COLON CANCER; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; PHOTOPHOBIA; PRIORITY JOURNAL; RETINA HEMORRHAGE; RETINA MACULOPATHY; RETINA VEIN OCCLUSION; SCOTOMA; SUBRETINAL FLUID; TERTIARY CARE CENTER; TREATMENT OUTCOME; UVEA DISEASE; UVEITIS; VISUAL IMPAIRMENT; CHEMICALLY INDUCED; CLINICAL TRIAL; EYE TUMOR; IMMUNOLOGY; METASTASIS; MULTICENTER STUDY; SECONDARY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; EYE NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; UVEITIS;

EID: 85032464761     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-017-3835-2     Document Type: Article

References (22)

1. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985–988
2. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319–322. https://doi.org/10.1126/science.291.5502.319
3. Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6:715–727. https://doi.org/10.1038/nri1936
4. Pauken KE, Wherry EJ (2015) Overcoming T cell exhaustion in infection and cancer. Trends Immunol 36:265–276. https://doi.org/10.1016/j.it.2015.02.008
5. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800. https://doi.org/10.1038/nm730
6. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO (2007) Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13:84–88. https://doi.org/10.1038/nm1517
7. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264. https://doi.org/10.1038/nrc3239
8. Mandala M, De Logu F, Merelli B, Nassini R, Massi D (2017) Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation. Lab Investig 97:166–175. https://doi.org/10.1038/labinvest.2016.132
9. Welsh SJ, Corrie PG (2015) Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 7:122–136. https://doi.org/10.1177/1758834014566428
10. Draganova D, Kerger J, Caspers L, Willermain F (2015) Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib. J Ophthal Inflamm Infect 5:17. https://doi.org/10.1186/s12348-015-0049-9
11. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB, Bluestone JA (1998) Molecular basis of T cell inactivation by CTLA-4. Science 282:2263–2266
12. Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Fala F, Fabbi M, Kato T, Lucarelli E, Donati D, Polito L, Bolognesi A, Ricci F, Salvi S, Gargaglione V, Mantero S, Alberghini M, Ferrara GB, Pistillo MP (2005) CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538–550. https://doi.org/10.1002/ijc.21155
13. Wolchok JD, Saenger Y (2008) The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13 Suppl 4:2–9. https://doi.org/10.1634/theoncologist.13-S4-2
14. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372–8377. https://doi.org/10.1073/pnas.1533209100
15. Karlin J, Gentzler R, Golen J (2016) Bilateral anterior uveitis associated with nivolumab therapy. Ocul Immunol Inflamm 1–3. https://doi.org/10.1080/09273948.2016.1215473
16. Aaberg MT, Aaberg TM Jr (2016) Pembrolizumab administration associated with posterior uveitis. Retin Cases Brief Rep. https://doi.org/10.1097/ICB.0000000000000368
17. Miserocchi E, Cimminiello C, Mazzola M, Russo V, Modorati GM (2015) New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient. Can J Ophthalmol 50:e2–e4. https://doi.org/10.1016/j.jcjo.2014.10.010
18. Kahloun R, Mbarek S, Khairallah-Ksiaa I, Jelliti B, Yahia SB, Khairallah M (2013) Branch retinal artery occlusion associated with posterior uveitis. J Ophthal Inflamm Infect 3:16. https://doi.org/10.1186/1869-5760-3-16
19. Linardou H, Gogas H (2016) Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med 4:272. 10.21037/atm.2016.07.10
20. Maezawa N, Yano A (1984) Two distinct cytotoxic T lymphocyte subpopulations in patients with Vogt-Koyanagi-Harada disease that recognize human melanoma cells. Microbiol Immunol 28:219–231
21. Caspi RR (2010) A look at autoimmunity and inflammation in the eye. J Clin Invest 120:3073–3083. https://doi.org/10.1172/JCI42440
22. Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK (2014) Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol 158:831–837.e832. https://doi.org/10.1016/j.ajo.2014.07.003